When a T cell’s receptor (TCR) detects a tumor antigen, it activates the NFΚB pathway, which subsequently promotes the proliferation and maturation of T cells that is crucial to effective anti-tumor responses. However, the molecular mechanisms that underlie the TCR-to-NFΚB signaling pathway are not well understood, so Dr. Traver’s work is investigating two relevant components―the POLKADOTS signalosome and the lesser known aggresome. She has discovered novel characteristics of each, and has shown that manipulation of these two complexes affects T cell activation. Moving forward, Dr. Traver’s continued investigations may uncover more insights that could be used to develop novel immunotherapy approaches.
Cutting-edge scientific research facilities tend to cluster in urban areas with a high cost of living, putting a financial squeeze on early career researchers. The financial support provided by CRI allows me and other fellows to focus our efforts on scientific breakthroughs, rather than on stressing about making ends meet.
Projects and Grants
Macroautophagic control of lymphocyte activation and proliferation
Foundation for the Advancement of Military Medicine | All Cancers, Lymphoma | 2015 | Brian C. Schaefer, Ph.D.
Let's spread the word about Immunotherapy! Click to share this page with your community.